Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996442154> ?p ?o ?g. }
- W2996442154 endingPage "32" @default.
- W2996442154 startingPage "32" @default.
- W2996442154 abstract "Metastatic castration resistant prostate cancer (mCRPC) relapses due to acquired resistance to docetaxel-based chemotherapy and remains a major threat to patient survival. In this report, we tested the effectiveness of a dual CXCR4/E-selectin antagonist, GM-I1359, in vitro and in vivo, as a single agent or in combination with docetaxel (DTX). This agent was compared to the single CXCR4 antagonist, CTCE-9908, and E-selectin antagonist, GMI-1271. Here we demonstrate that CXCR4 antagonism reduced growth and enhanced DTX treatment in PCa cell lines as well as restored DTX effectiveness in DTX-resistant cell models. The efficacy of dual antagonist was higher respect to those observed for single CXCR4 antagonism. GM1359 impacted bone marrow colonization and growth in intraventricular and intratibial cell injection models. The anti-proliferative effects of GMI-1359 and DTX correlated with decreased size, osteolysis and serum levels of both mTRAP and type I collagen fragment (CTX) in intra-osseous tumours suggesting that the dual CXCR4/E-selectin antagonist was a docetaxel-sensitizing agent for bone metastatic growth. Single agent CXCR4 (CTCE-9908) and E-selectin (GMI-1271) antagonists resulted in lower sensitizing effects compared to GMI-1359. These data provide a biologic rationale for the use of a dual E-selectin/CXCR4 inhibitor as an adjuvant to taxane-based chemotherapy in men with mCRPC to prevent and reduce bone metastases." @default.
- W2996442154 created "2019-12-26" @default.
- W2996442154 creator A5002876711 @default.
- W2996442154 creator A5008951735 @default.
- W2996442154 creator A5009201287 @default.
- W2996442154 creator A5016735563 @default.
- W2996442154 creator A5026350592 @default.
- W2996442154 creator A5026640374 @default.
- W2996442154 creator A5039243219 @default.
- W2996442154 creator A5047952766 @default.
- W2996442154 creator A5049625129 @default.
- W2996442154 creator A5054340572 @default.
- W2996442154 creator A5080888531 @default.
- W2996442154 creator A5083231815 @default.
- W2996442154 date "2019-12-20" @default.
- W2996442154 modified "2023-10-06" @default.
- W2996442154 title "Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth" @default.
- W2996442154 cites W1421449014 @default.
- W2996442154 cites W1485310670 @default.
- W2996442154 cites W1495074401 @default.
- W2996442154 cites W1785704905 @default.
- W2996442154 cites W1874698854 @default.
- W2996442154 cites W1886771640 @default.
- W2996442154 cites W1965091140 @default.
- W2996442154 cites W1969878202 @default.
- W2996442154 cites W1979061661 @default.
- W2996442154 cites W1982432532 @default.
- W2996442154 cites W1988486794 @default.
- W2996442154 cites W1990287298 @default.
- W2996442154 cites W1999360473 @default.
- W2996442154 cites W2000064968 @default.
- W2996442154 cites W2001471842 @default.
- W2996442154 cites W2002626138 @default.
- W2996442154 cites W2019307617 @default.
- W2996442154 cites W2027185963 @default.
- W2996442154 cites W2028610455 @default.
- W2996442154 cites W2033890749 @default.
- W2996442154 cites W2047287874 @default.
- W2996442154 cites W2049023072 @default.
- W2996442154 cites W2055878176 @default.
- W2996442154 cites W2058053962 @default.
- W2996442154 cites W2059085904 @default.
- W2996442154 cites W2070793750 @default.
- W2996442154 cites W2071044199 @default.
- W2996442154 cites W2072122053 @default.
- W2996442154 cites W2096444752 @default.
- W2996442154 cites W2104163970 @default.
- W2996442154 cites W2104387616 @default.
- W2996442154 cites W2125146007 @default.
- W2996442154 cites W2133207578 @default.
- W2996442154 cites W2134950344 @default.
- W2996442154 cites W2137293812 @default.
- W2996442154 cites W2137330819 @default.
- W2996442154 cites W2138959855 @default.
- W2996442154 cites W2148806906 @default.
- W2996442154 cites W2151635781 @default.
- W2996442154 cites W2161258086 @default.
- W2996442154 cites W2165613795 @default.
- W2996442154 cites W2167147051 @default.
- W2996442154 cites W2169669596 @default.
- W2996442154 cites W2170075711 @default.
- W2996442154 cites W2253090940 @default.
- W2996442154 cites W2266814182 @default.
- W2996442154 cites W2282034100 @default.
- W2996442154 cites W2288959164 @default.
- W2996442154 cites W2297905809 @default.
- W2996442154 cites W2411217257 @default.
- W2996442154 cites W2474801162 @default.
- W2996442154 cites W2547937667 @default.
- W2996442154 cites W2557360717 @default.
- W2996442154 cites W2610022348 @default.
- W2996442154 cites W2610351483 @default.
- W2996442154 cites W2749596444 @default.
- W2996442154 cites W2768493050 @default.
- W2996442154 cites W2797011482 @default.
- W2996442154 cites W2801462738 @default.
- W2996442154 cites W2890435361 @default.
- W2996442154 cites W2897733945 @default.
- W2996442154 cites W2905036361 @default.
- W2996442154 cites W2915478882 @default.
- W2996442154 cites W2950725795 @default.
- W2996442154 cites W2969795870 @default.
- W2996442154 cites W4293409513 @default.
- W2996442154 doi "https://doi.org/10.3390/cells9010032" @default.
- W2996442154 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7017374" @default.
- W2996442154 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31877673" @default.
- W2996442154 hasPublicationYear "2019" @default.
- W2996442154 type Work @default.
- W2996442154 sameAs 2996442154 @default.
- W2996442154 citedByCount "20" @default.
- W2996442154 countsByYear W29964421542020 @default.
- W2996442154 countsByYear W29964421542021 @default.
- W2996442154 countsByYear W29964421542022 @default.
- W2996442154 countsByYear W29964421542023 @default.
- W2996442154 crossrefType "journal-article" @default.
- W2996442154 hasAuthorship W2996442154A5002876711 @default.
- W2996442154 hasAuthorship W2996442154A5008951735 @default.
- W2996442154 hasAuthorship W2996442154A5009201287 @default.